The role of statins in the prevention of contrast induced nephropathy: a meta-analysis of 8 randomized trials

Journal of Thrombosis and Thrombolysis

Volumn 38, Issue 4, 2014, Pages 493-502

  Barbieri, Lucia ^a   Verdoia, Monica ^a   Schaffer, Alon ^a   Nardin, Matteo ^a   Marino, Paolo ^a   De Luca, Giuseppe ^a  

^a UNIVERSITY OF EASTERN PIEDMONT   (Italy)

Author keywords

Contrast induced nephropathy; Percutaneous intervention; Statin therapy

Indexed keywords

ACETYLCYSTEINE; ATORVASTATIN; CONTRAST MEDIUM; CREATININE; FENOLDOPAM; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PLACEBO; ROSUVASTATIN; SIMVASTATIN; SODIUM CHLORIDE;

ACUTE CORONARY SYNDROME; ALKALINIZATION; ANGIOCARDIOGRAPHY; ANTIINFLAMMATORY ACTIVITY; ANTIOXIDANT ACTIVITY; ARTICLE; CONTRAST INDUCED NEPHROPATHY; CONTROLLED STUDY; CREATININE BLOOD LEVEL; CREATININE CLEARANCE; DIABETES MELLITUS; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG MEGADOSE; HEART EJECTION FRACTION; HEMODIALYSIS; HEMOFILTRATION; HUMAN; HYDRATION; INCIDENCE; LOW DRUG DOSE; META ANALYSIS; NON ST SEGMENT ELEVATION MYOCARDIAL INFARCTION; OUTCOME ASSESSMENT; PERCUTANEOUS CORONARY INTERVENTION; PLEIOTROPY; RANDOMIZED CONTROLLED TRIAL; ST SEGMENT ELEVATION MYOCARDIAL INFARCTION; TRANSLUMINAL CORONARY ANGIOPLASTY; ACUTE KIDNEY INJURY; CHEMICALLY INDUCED; DIAGNOSTIC USE; PROCEDURES; RANDOMIZED CONTROLLED TRIAL (TOPIC);

ACUTE KIDNEY INJURY; CONTRAST MEDIA; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; RANDOMIZED CONTROLLED TRIALS AS TOPIC;

EID: 84910146061     PISSN: 09295305     EISSN: 1573742X     Source Type: Journal    
DOI: 10.1007/s11239-014-1076-3     Document Type: Article

References (50)

1. McCullough PA (2008) Contrast-induced acute kidney injury. J Am Coll Cardiol 51:1419–1428
2. James MT, Gali WA et al (2010) Acute kidney injury following coronary angiography is associated with a long-term decline in kidney funcion. Kidney Int 78:803–809
3. Nash K, Hafeez A, Hou S et al (2002) Hosputal acquired renal insufficiency. Am J Kidney Dis 39:930–936
4. McCullough PA (2008) Contrast-induced acute kidney injury. J Am Coll Cardiol 51:1419–1428
5. Maeder M, Klein M, Fehr T et al (2004) Contrast nephropathy: review focusing on prevention. J Am Coll Cardiol 44:1763–1771
6. De Luca G, Bellandi F, Huber K et al (2011) Early glycoprotein IIb-IIIa inhibitors in primary angioplasty-abciximab long-term results (EGYPT-ALT) cooperation: individual patient’s data meta-analysis. J Thromb Haemost 9:2361–2370
7. De Luca G, Cassetti E, Verdoia M et al (2009) Bivalirudin as compared to unfractionated heparin among patients undergoing coronary angioplasty: a meta-analyis of randomised trials. Thromb Haemost 102(3):428–436
8. Di Lorenzo E, Sauro R, Varricchio A et al (2009) Benefits of drug-eluting stents as compared to bare metal stent in ST-segment elevation myocardial infarction: 4-year results of the PaclitAxel or Sirolimus-Eluting stent vs bare metal stent in primary angiOplasty (PASEO) randomized trial. Am Heart J 158(4):e43–e50
9. Navarese EP, Kubica J, Castriota F et al (2011) Safety and efficacy of biodegradable vs. durable polymer drug-eluting stents: evidence from a meta-analysis of randomised trials. EuroIntervention 7:985–994
10. De Luca G, Dirksen MT, Spaulding C et al (2012) Drug-Eluting Stent in Primary Angioplasty (DESERT) Cooperation. Drug-eluting vs. bare-metal stents in primary angioplasty: a pooled patient-level meta-analysis of randomized trials. Arch Intern Med 172:611–621
11. Merten GJ, Burgess WP, Gray LV et al (2004) Prevention of contrast-induced nephropathy with sodium bicarbonate: a randomized controlled trial. JAMA 291:2328–2334
12. From AM, Bartholmai BJ, Williams AW et al (2008) Sodium bicarbonate is associated with an increased incidence of conrast nephropathy: a retrospective study. Clin J Am Soc Nephrol 3:10–18
13. Marenzi G, Assanelli E, Marana I et al (2006) N-Acetylcysteine and contrast-induced nephropathy in primary angioplasty. NEJM 354:2773–2782
14. Stone GW, McCullough PA, Tumlin JA et al (2003) CONTRAST Investigators. Fenoldopam mesylate for the prevention of contrast-induced nephropathy: a randomized controlled trial. JAMA 290:2284–2291
15. Schindler R, Stahl C, Venz S et al (2001) Removal of contrast media by different extracorporeal treatments. Nephrol Dial Transplant 16:1471–1474
16. Marenzi G, Marana I, Lauri G et al (2003) The prevention of radiocontrast-agent-induced nephropathy by hemofiltration. N Engl J Med 349:1333–1340
17. Pannu N, Wiebe N, Tonelli M (2006) Prophylaxis strategies for contrast-induced nephropathy. JAMA 295:2765–2779
18. Barrett BJ, Parfrey PS (2006) Preventing nephropathy induced by contrast medium. NEJM 354:379–386
19. Ridker PM, Rifai N, Clearfield M et al (2001) Measurement of C-reactive protein for the targeting of statin therapy in the primary prevention of acute coronary events. N Engl J Med 344:1959–1965
20. Zhang BC, Li WM, Xu YW et al (2011) High-dose statin pre-treatment for the prevention of contrast induced nephropathy: a meta analysis. Can J Cardiol 27:851–858
21. Khanal S, Attallah N, Smith DE et al (2005) Statin therapy reduces contrast induced nephropathy: an analysis of contemporary percutaneous interventions. Am J Med 118:843–849
22. Attallah N, Yassine L, Musial J et al (2004) The potential role of statins in contrast nephropathy. Clin Nephrol 62:273–278
23. Zhao JL, Yang YJ, Zhang YH et al (2008) Effect of statins on contrast induced nephropathy in patients with acute myocardial infarction treated with primary angioplasty. Int J Cardiol 126:435–436
24. Yoshida S, Kamihata H, Nakamura S et al (2009) Prevention of contrast induced nephropathy by chronic pravastatin treatment in patients with cardiovascular disease and renal insufficiency. J Cardiol 54:192–198
25. Kandula P, Shah R, Singh N et al (2010) Statins for prevention of contrast induced nephropathy in patients undergoing non-emergent percutaneous coronary intervention. Nephrology 15:165–170
26. Jadad AR, Moore RA, Carroll D et al (1996) Assessing the quality of reports of randomized clinical trials: is blinding necessary? Control Clin Trials 17:1–12
27. Biondi-Zoccai GG, Abbate A, Agostoni P et al (2003) Stenting versus surgical bypass grafting for coronary artery disease: systematic overview and meta-analysis of randomized trials. Ital Heart J 4:271–280
28. Liberati A, Altman DG, Tetzlaff J et al (2009) The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration. Ann Intern Med 151:W65–W94
29. Ozhan H, Erden I, Ordu S et al (2010) Efficacy of short-term high-dose atorvastatin for prevention of contrast-induced nephropathy in patients undergoing coronary angiography. Angiology 61(7):711–714
30. Acikel S, Muderrisoglu H, Yldirir A et al (2010) Prevention of contrast induced impairment of renal function by short term or long term statin therapy in patients undergoing elective coronary angiography. Blood Coagul Fibrinolysis 21(8):750–757
31. Li W, Fu W, Wang Y et al (2012) Beneficial effects of high dose atorvastatin pretreatment on renal function in patients with acute ST-segment elevation myocardial infarction undergoing emergency percutaneous coronary intervention. Cardiology 122:195–202
32. Jo Sang-Ho, Koo Bon-Know, Park Jin-Shik et al (2008) Prevention of radiocontrast medium induced nephropathy using short-term high-dose simvastatin in patients with renal insufficiency undergoing coronary angiography (PROMISS) trial-a randomized controlled study. Am Heart 155:499.e1–499.e8
33. Toso A, Maioli M, Leoncini M et al (2010) Usefulness of Atorvastitin (80 mg) in prevention of contrast induced nephropathy in patients with chronic renal disease. Am J Cardiol 105:288–292
34. Patti G, Ricottini E, Nusca A et al (2011) Short term, high-dose Atorvastatin pre-treatment to prevent contrast induced nephropathy in patients with acute coronary syndrome undergoing percutaneous coronary interventions (from the ARMYDA CIN trial). Am J Cardiol 108:1–7
35. Leoncini M, Toso A, Maioli M et al (2014) Early high-dose Rosuvastatin for contrast induced nephropathy prevention in acute coronary syndrome. J Am Coll Cardiol 63:71–79
36. Han Y, Zhu G, Han L et al (2014) Short term Rosuvastatin therapy for prevention of contrast induced acute kidney injury in patients with diabetesand chronic kidney disease. J Am Coll Cardiol 63:62–70
37. De Luca G, Navarese EP, Suryapranata H (2013) A meta-analytic overview of thrombectomy during primary angioplasty. Int J Cardiol 166:606–612
38. De Luca G, Navarese EP, Cassetti E et al (2011) Meta-analysis of randomized trials of glycoprotein IIb/IIIa inhibitors in high-risk acute coronary syndromes patients undergoing invasive strategy. Am J Cardiol 107:198–203
39. Navarese EP, De Luca G, Castriota F et al (2011) Low-molecular-weight heparins vs. unfractionated heparin in the setting of percutaneous coronary intervention for ST-elevation myocardial infarction: a meta-analysis. J Thromb Haemost 9:1902–1915
40. Capozzolo C, Piscione F, De Luca G et al (2001) Direct coronary stenting: effect on coronary blood flow, immediate and late clinical results. Catheter Cardiovasc Interv 53:464–473
41. Gueler F, Rang S, Park JK et al (2002) Post ischemic acute renal failure is reduced by short term statin treatment in a rat model. J Am Soc Nephrol 13:2288–2298
42. Park JK, Muller DN, Mervala EM et al (2000) Carivastatin prevents angiotensin II induced renal injury independent of blood pressure and cholesterol-lowering effects. Kidney Int 58:1420–1430
43. Bonetti PO, Lerman LO, Napoli C et al (2003) Statin effects beyond lipid lowering: are they clinical relevant? Eur Heart J 24:225–248
44. Ichiki T, Takeda K, Tokunou T et al (2001) Dowregulation of angiotensin II type 1 receptor by hydrophobic 3 –hydroxy-3methylglutaryl coenzyme A reductase inhibitors in vascular smooth muscle cells. Arterioscler Thromb Vasc Biol 21:1896–1901
45. Pappy R, Stavrakis S, Hennebry TA et al (2011) Effect of statin therapy on contrast induced nephropathy after coronary angiography: a meta-analysis. Int J Cardiol 15:348–353
46. Zhang T, Shen LH, Hu LH et al (2011) Statins for the prevention of contrast induced nephropathy: a systematic review and meta-analysis. Am J Nephrol 33:344–351
47. Zhou Y, Yuan WJ, Zhu N et al (2011) Short term, high dose statins in the prevention of contrast induced nephropathy: a systematic review and meta-analysis. Clin Nephrol 76:475–483
48. Zhang BC, Li WM, Xu YW et al (2011) High-dose statin pretreatment for the prevention of contrast-induced nephropathy: a meta-analysis. Can J Cardiol. 27(6):851–858
49. Li Y, Liu Y, Fu L et al (2012) Efficacy of short-term high-dose statin in preventing contrast-induced nephropathy: a meta-analysis of seven randomized controlled trials. PLoS One 7(4):e34450
50. Lameire N, Kellum JA, for the KDIGO AKI Guideline Work Group (2013) Contrast-induced acute kidney injury and renal support for acute kidney injury: a KDIGO summary (Part 2). Crit Care 17:205 (in press)